Introduction

Benign prostatic hyperplasia (BPH) is one of the most common benign tumors in men and is estimated to produce symptomatic disease in 40% of men over 60 years of age. The long-term solution of surgical intervention is more effective than current drug therapy, but the number of drug-treated patients could rise dramatically, from just 10%, as new types of drug reach late stage clinical development. 

Scope

Overview of the disease pathology, presentation patterns and diagnosis 

Detailed analysis of the treatment options a urologist uses to treat BPH 

Review of the drugs currently in development for BPH

Report Highlights

Alpha-blockers and 5alpha-reductase inhibitors are being combined to increase the efficacy of drug treatment for BPH, creating a niche for a co-packaged product. 

Phase II agent ML-04 has produced good efficacy and tolerability data, but Milkhaus still need a marketing partner to make the drug a success. 

The investigation of LHRH analogs in BPH may provide a route to prolonged patent protection for AstraZeneca’s Zoladex and Abbott/Takeda/TAP’s Lupron. 

Reasons to Purchase

Define the underserved drug-treatable symptomatic BPH population and how to gain access to these patients 

Identify the drug classes in development and to what degree they satisfy the unmet needs in the BPH market 

Understand the current treatment patterns for BPH and how your product fits into the marketplace 

Publisher: Datamonitor Oncology Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Oncology.html#a258